Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

Gualtiero Ricciardi, A Diamantopoulos, M Benucci, S Capri, W Berger, N Wintfeld, Giulio Giuliani

Research output: Contribution to journalArticle

36 Citations (SciVal)

Abstract

This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer's perspective in Italy.
Original languageEnglish
Pages (from-to)576-585
Number of pages10
JournalJournal of Medical Economics
Volume15
DOIs
Publication statusPublished - 2012

Keywords

  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Female
  • Health Care Costs
  • Health Resources
  • Humans
  • Italy
  • Male
  • Quality of Life
  • Quality-Adjusted Life Years
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha

Fingerprint

Dive into the research topics of 'Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy'. Together they form a unique fingerprint.

Cite this